Acadia Pharmaceuticals Announces Dr. Elizabeth H.Z. Thompson's Retirement and Continued Consulting Role
- Acadia Pharmaceuticals announces Dr. Elizabeth H.Z. Thompson's retirement as Head of Research and Development.
- Dr. Thompson will continue as a consultant until at least the end of 2026.
- Acadia emphasizes stability for its Alzheimer's disease psychosis pipeline during upcoming clinical trials.
Acadia Pharmaceuticals announces the upcoming retirement of Dr. Elizabeth H.Z. Thompson, the current Head of Research and Development. Dr. Thompson will transition out of her role while continuing her involvement with the company as a consultant until at least the end of 2026. This consulting position is part of Acadia's strategy to ensure continuity for its pipeline, particularly focusing on ongoing work related to Alzheimer's disease psychosis.
Strategic Transition in Leadership
The planned transition comes at a critical time for Acadia Pharmaceuticals as it seeks to advance its treatments for central nervous system conditions. With ongoing preparations for key clinical trials, maintaining stable leadership is critical as the company progresses toward a significant Phase 2 clinical readout. This stage is vital for the future of their therapeutic pipeline, especially in addressing the complexities of Alzheimer's-related psychosis.
Commitment to Neuroscience Innovations
Acadia is dedicated to enhancing its contributions to the field of neuroscience and providing effective treatment solutions for patients. The upcoming Phase 3 trials underline the company's commitment to pushing forward with innovative research aimed at addressing challenging health conditions. Dr. Thompson's role as a consultant will play a crucial part in ensuring that this momentum continues as the company navigates through pivotal phases of drug development.